Depressive Disorder, Treatment-Resistant Clinical Trial
Official title:
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms in participants with treatment-resistant depression (TRD) who are in stable remission after an induction and optimization course of intranasal esketamine plus an oral antidepressant.
This is a randomized, double-blind (neither the researchers nor the participant know what treatment the participants is receiving), active-controlled, multicenter (more than 1 study site) study in participants with TRD to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms. The study will consist of 5 phases: Screening/Prospective Observational Phase (4-7weeks) for direct-entry participants only, Open-label Induction Phase (4-weeks) for direct-entry participants only, Optimization Phase (12-weeks; open-label for direct-entry participants and double-blind for transferred-entry participants), Maintenance Phase (variable duration; double-blind for all participants) and Follow-up Phase (2-weeks). Participants' safety will be monitored throughout the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03851380 -
Improving Brain Stimulation Through Imaging
|
||
| Completed |
NCT04977674 -
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
|
Early Phase 1 | |
| Completed |
NCT03207282 -
Treatment Resistant Depression in America Latina
|
||
| Completed |
NCT02691520 -
Epidemiology of Treatment Resistant Depression in Taiwan
|
Phase 4 | |
| Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
| Active, not recruiting |
NCT04159012 -
NESBID: Neuro-Stimulation of the Brain in Depression
|
N/A | |
| Recruiting |
NCT05870501 -
Synaptic Imaging and Network Activity in Treatment Resistant Depression
|
N/A | |
| Completed |
NCT04239651 -
rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD)
|
N/A | |
| Completed |
NCT04599855 -
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
|
Phase 4 | |
| Completed |
NCT03283670 -
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
|
Phase 2 | |
| Recruiting |
NCT03004521 -
Lithium Versus Quetiapine in Treatment Resistant Depression
|
Phase 4 | |
| Recruiting |
NCT04783103 -
Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study
|
N/A | |
| Completed |
NCT03434041 -
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
| Terminated |
NCT03887624 -
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
|
Early Phase 1 | |
| Completed |
NCT02577250 -
Ketamine Infusions for PTSD and Treatment-Resistant Depression
|
Phase 1 | |
| Recruiting |
NCT02610712 -
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
|
Phase 4 | |
| Completed |
NCT03051256 -
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
|
Phase 2 | |
| Enrolling by invitation |
NCT05581797 -
Psilocybin-assisted Interpersonal Therapy for Depression
|
N/A | |
| Completed |
NCT02782104 -
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
|
Phase 3 | |
| Completed |
NCT04216888 -
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
|
Phase 2/Phase 3 |